All In Biotech

Drug Trial Radar · NCT01585298

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

6,998

Actual

Start

Apr 29, 2012

Primary completion

Dec 12, 2016

Study completion Dec 12, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.

Conditions

  • Multiple Sclerosis

Interventions

  • FTY720Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With 2nd or 3rd Degree Atrioventricular (AV) BlockTime frame: baseline, during 6 hour monitoring post first dose observation
  2. Number of Patients With Heart Rate Below 45 Beats Per Minute (BPM)Time frame: baseline during 6 hour monitoring post dose

Locations

258 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Aalen, Germany

  • Novartis Investigative Site

    Aalen-Wasseralfingen, Germany

  • Novartis Investigative Site

    Abensberg, Germany

  • Novartis Investigative Site

    Achim, Germany

  • Novartis Investigative Site

    Aichach, Germany

  • Novartis Investigative Site

    Altenburg, Germany

  • Novartis Investigative Site

    Alzenau in Unterfranken, Germany

  • Novartis Investigative Site

    Andernach, Germany

  • Novartis Investigative Site

    Asbach, Germany

  • Novartis Investigative Site

    Aschaffenburg, Germany

  • Novartis Investigative Site

    Augsburg, Germany

  • Novartis Investigative Site

    Bad Berka, Germany

  • Novartis Investigative Site

    Bad Hersfeld, Germany

  • Novartis Investigative Site

    Bad Homburg, Germany

  • Novartis Investigative Site

    Bad Honnef, Germany

  • Novartis Investigative Site

    Bad Krozingen, Germany

  • Novartis Investigative Site

    Bad Mergentheim, Germany

  • Novartis Investigative Site

    Bad Saarow, Germany

  • Novartis Investigative Site

    Bad Wildbad, Germany

  • Novartis Investigative Site

    Bamberg, Germany

  • Novartis Investigative Site

    Bayreuth, Germany

  • Novartis Investigative Site

    Berg, Germany

  • Novartis Investigative Site

    Bergisch Gladbach, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

Showing 40 of 258 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.